NCT03157804 Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A Status COMPLETED Phase PHASE1/PHASE2
NCT03147612 Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03100877 Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Status WITHDRAWN Phase PHASE1/PHASE2
NCT03077542 Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT03019640 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Status COMPLETED Phase PHASE2
NCT03007147 Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT02960646 Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Status COMPLETED Phase PHASE1
NCT02943733 Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs Status TERMINATED Phase PHASE1
NCT02931071 Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1 Status COMPLETED Phase PHASE2
NCT02921061 Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Status COMPLETED Phase PHASE1/PHASE2
NCT02880293 Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor Status COMPLETED Phase NA
NCT02806791 Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment Status UNKNOWN Phase N/A
NCT02802852 Proteomics and Stem Cell Therapy as a New Vascularization Strategy Status COMPLETED Phase NA
NCT02791919 Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia Status WITHDRAWN Phase PHASE1
NCT02756572 Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Status COMPLETED Phase PHASE2
NCT02728531 Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma Status COMPLETED Phase PHASE1
NCT02728050 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Status COMPLETED Phase PHASE1/PHASE2
NCT02703051 A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects Status COMPLETED Phase PHASE1